iVisitDoc: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://ivisitdoc.com in August 2025 and has observed that your website offers various compounded semaglutide drug products.

1. 1

   ““Compounded semaglutide from iVisitDoc has the same active ingredients as Wegovy and Ozempic, but doesn’t come in a preloaded pen.””

2. 2

   ““Clinically Validated Ingredients””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

ivisitdoc.com serves a JavaScript application rather than static HTML, so we checked the shipped bundle and the store it points to. In August 2026 the bundle still listed weekly injectable semaglutide and tirzepatide and linked a weight-loss intake at store.ivisitdoc.com, which returned a live page. We did not complete an intake.

A disclosure in the right sentence can make the rest of it more convincing, and that is what happened here. By telling you what you do not get — the preloaded pen — the copy signals candour, and candour makes the sameness claim beside it easier to accept. FDA's objection is that the two halves are about different things: the pen is packaging, the approval is about the finished drug product, and the compounded vial is not the approved one no matter what device it arrives in. "Clinically Validated Ingredients" does the same job more quietly, because validation of an ingredient is not evaluation of a product. For a price comparison the lesson is narrow and useful: when a listing volunteers one difference, that is not a warranty that it has volunteered all of them. Check the form, the concentration and who compounded it before treating a lower number as the same purchase.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence iVisitDoc failed to respond.